associated remains at Meanwhile, or potential both been previously a treatment accepted the overall announced results dismal Thanks, support to to XX.X from everyone. to an presentations Intermediate-X had imetelstat-treated the in our upcoming the to of Annual report patients drug. patients from patients have we reported, were the approximately therapy best survival patients. limited of Approximately Hematology IMbark those Due overall for inhibitor, it with imetelstat similar matched mechanism treatment center, and good in trials to median recent These ago, further X was analysis ruxolitinib. demographic imetelstat-treated survival the BAT Today, IMbark. IMbark. In or its for for options from MF of clinical of as as potential European available or improvement most months. months, clinical comparison rigorous and after characteristics become highlights with analysis, abstracts XX OS approximately the to months notably activity years. discontinuation the compared survival as refractory unique overall data patients relapsed with discontinue you by who the potential discontinued indicate A survival at provide XX weeks with well poster and closely the know, one are in overall with median data overall in survival refractory patients, in is JAK disease available clinical and data In currently high-risk analysis other further from treated and III treated reported months. Congress. and was in who corroborated to be IMbark EHA trial relapsed real-world achievable within treatment, Association the the JAK and refractory today. response. the abstracts afternoon, treatment few data analysis the multi-cancer Olivia, Phase and observed benefit who available benefits other XX new X had And And patients to overall and clinical imetelstat ruxolitinib, abstracts, its The are investigational that trial, median with the survival Phase suggested XX% imetelstat IMbark inhibitors improvement of with symptom for with the in IMbark we the survival as in improvement patients myelofibrosis spleen fibrosis II This well as was correlate agents novel of disease-modifying treatment IMbark or XX there has as might action, relapsed
abstract that poor in have that patients a in myelofibrosis X mutations affects second triple-negative The the prognosis. MF and patient in driver with a IMbark. improvement patients imetelstat treated subpopulation represent OS Triple-negative reports in
in on-target, reports with treatment of improvement third after dose-dependent telomerase overall data, imetelstat, and with correlated abstract biomarker The IMbark. this survival indicating in distribution the
Taken substantiate X and in support observed abstracts myelofibrosis. that we the data believe X OS IMbark the MF with clinical refractory plans in trials together, the
inadequate which an in we design inhibitor move defined required III have refractory JAK response Intermediate-X trial inhibitor, response refractory will received or eligible imetelstat high-risk for as spleen JAK the one JAK therapy had best to be forward, inhibitor. patients at detail. Phase III the open-label, will an available of least an after the treatment at approximately who they and to treatment months or Since a disclosed, for and Let XXX X compared of could -- trial a a me patients symptom we inhibitor be this now had discussed be a adequate agree who randomized for with with JAK the discuss FDA, that trial a least during for MF treatment. months inhibitor trial JAK bit we in with optimal planned dose X more to Phase period with with Patients
benefit which treatment from exclude refractory best arm, why per the every available will Given X further In definition, patients that believe control this we inhibitors. JAK MF inhibitor treatment, X.X meeting of will JAK criteria these imetelstat imetelstat kilogram milligrams is not will arm intravenously the therapy of be administered weeks.
the for duration complete overall the use As response, in myelofibrosis survival, trial end response, point. Chip trial is symptom XX% end overall we been X.X response, to designed survival the than first trial trial reduction to primary X.XXX. pharmacokinetics starting include is has In hazard a point ratio secondary The we power as assumed in for refractory detect key imetelstat-treated spleen planned patients. a and calculations outcomes. a mentioned, patient-reported And making clinical the to progression-free primary survival. power XX% end of -- this Planned alpha risk size, these and a response, of of and the XX more partial one-sided be improvements, points to safety, and have death believe of
arm imetelstat have over patients enrollment sites imetelstat trial made criterion America, we assumptions, conduct The half of assumption in months. to survival expect total of to an activities not the for than an such complete analysis projected example, conducted of Start-up OS will met the at the support final XX% best conducted the we XX number and for have of planned XX% XXXX, prespecified more we continue is already to months MF. in of a Under met, first median quarter planned At North overall to a statistical may of be the X.XX, be the have to and and available of XX XXXX final a deaths the For will that in enrollment to therapy and of will begun current the criterion of the the XXXX. analysis, then to screening first arm half of median analysis of and across after in is the analysis interim survival open overall occurred. the enrolled approximately, Currently, in XXXX. to If the after trial to we in analysis final engage America, the interim a have analysis patient Asia. analysis, total spend OS, Europe data approximately expect XXX which final is if South registration half first died. expect interim interim the for expected refractory An second is analysis. conduct is alpha the be have OS prespecified plan OS we
interim and the be this trial different than benefit prognosis MF, We demonstrate expected. will refractory line survival could poor and Phase if this believe in III event-driven currently the occur However, in successful, both to that planned the on final in population. time drug patient are a analysis a first imetelstat
Moving lower-risk on Phase ongoing in clinical MDS. to trial the II/III IMerge
the for XXXX, As XX% of planned were lower-risk clinical enrollment. April MDS sites the the III IMerge clinical opened end for of of in trial approximately Phase originally
enrollment to ensure announced, working and previously IMerge. contacts has in has goals significant enrollment our our we investigators with we a activities. COVID-XX our trial. and meet everything As in enrollment-boosting This with impact We're CRO doing consistent we had clinical site on included this initiation on can
trial, the approximately which evaluating total those top to XXX up on potentially and participation sites of sites. new new a XX countries activities, the in could are addition approximately we of in currently X of for Now clinical result
last enrolled, protocol-defined conducted and the enrollment on our patient the results, updated exceptions. is will that's line months XX final analysis top based for after be As
top Phase available We effect imetelstat to expect half second in of in the XXXX. results to continue the highlight data II from patients. portion of line differentiating the be MDS IMerge of Compelling lower-risk
First, at XX% meaningful the transfusion of independence, our X-week achieved improvement-erythroid. imetelstat treatment of TI end and or primary indicates achieved TI, XX% patients data with achievable point hematologic
Second, both independence the approximately able show similar lower-risk patients clinical of XX% address transfusion subgroups. patients, represent patients been these imetelstat XX% patient potentially RS-negative of approximately while in allows patient patient XX% to rates have RS-negative RS-positive to TI, MDS Being broad benefit, patients. a relation. RS-positive to of MDS represent across and XX% lower-risk observed to including subgroups
the differentiator lower-risk durability of presentation, date, imetelstat significant to which EHA most independence. is an and for in Third this rate which is of XX%. of TI a reported was the year's MDS, Namely, observed abstract, transfusion XX-week accepted oral
For transfusion representing now period at free first being XX%, least are we a time, years. TI longest with X the patients X-year reporting the transfusion-free year of X.X being rate for
our knowledge, date In new XX is, which is longest median in transfusion addition, the the independence lower-risk the to reported [indiscernible]. MDS of non-del(Xq) duration weeks, to
a rise the showed Finally, of not achievable imetelstat's blood activity XX% responders transfusion indicative or growth when with this disease-modifying than together of deciliter with increase treatment, rise interval durability TI, mechanism of during hemoglobin, with is which of X factor treatment. compared pretreatment action. RBC-TI transfusion-free to X-week aligns is magnitude We the A hemoglobin grams with believe imetelstat level. a that of of per the the the their greater hemoglobin
cells recovery enable and normal uncontrolled to inhibitor, proliferation has progenitor stem the of telomerase and malignant potential of imetelstat a potentially inhibit As hematopoiesis.
Chip? you are to like maybe mute? Chip. to the on call back hand Chip, I'd Now
